title: Identification of a transiently exposed VE-cadherin epitope that allows for specific targeting of an antibody to the tumor neovasculature.
abstract: VE-cadherin is an adhesion molecule localized at the adherens junctions of endothelial cells. It is crucial for the proper assembly of vascular structures during angiogenesis and maintaining vascular integrity. We have studied 3 monoclonal antibodies (mAbs) against murine VE-cadherin that inhibit angiogenesis and tumor growth. Two of these, BV13 and 10G4, also disrupted normal vessels, resulting in severe vascular leakage, whereas the third, E4G10, did not. The goal of the current report was to identify the epitope of E4G10 and distinguish it from those of the disruptive mAbs. We mapped the epitope of E4G10 to within the first 10 amino acids of mature VE-cadherin and demonstrated that conserved tryptophan residues in this sequence are required for VE-cadherin-mediated trans-adhesion. The disruptive mAbs target a different epitope within amino acids 45 to 56, which structural homology modeling suggests is not involved in trans-adhesion. From our studies, we hypothesize that E4G10 can only bind the neovasculature, where VE-cadherin has not yet engaged in trans-adhesion and its epitope is fully exposed. Thus, E4G10 can inhibit junction formation and angiogenesis but is unable to target normal vasculature because its epitope is masked. In contrast, BV13 and 10G4 bind an epitope that is accessible regardless of VE-cadherin interactions, leading to the disruption of adherens junctions. Our findings establish the immediate N-terminal region of VE-cadherin as a novel target for inhibiting angiogenesis.
authors.affiliation: ImClone Systems Incorporated, 180 Varick St, New York, NY 10014, USA.
authors.forename: Chad
authors.initials: C
authors.lastname: May
authors.forename: Jacqueline F
authors.initials: JF
authors.lastname: Doody
authors.forename: Rashed
authors.initials: R
authors.lastname: Abdullah
authors.forename: Paul
authors.initials: P
authors.lastname: Balderes
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Xu
authors.forename: Chien Peter
authors.initials: CP
authors.lastname: Chen
authors.forename: Zhenping
authors.initials: Z
authors.lastname: Zhu
authors.forename: Lawrence
authors.initials: L
authors.lastname: Shapiro
authors.forename: Paul
authors.initials: P
authors.lastname: Kussie
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Hicklin
authors.forename: Fang
authors.initials: F
authors.lastname: Liao
authors.forename: Peter
authors.initials: P
authors.lastname: Bohlen
mesh_terms: D020533:Angiogenesis Inhibitors; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D015703:Antigens, CD; D000951:Antigens, Neoplasm / Q000276:immunology; D015820:Cadherins / Q000276:immunology*; D002199:Capillary Permeability / Q000187:drug effects; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D004730:Endothelium, Vascular; D018604:Epitope Mapping; D000939:Epitopes; D007365:Intercellular Junctions / Q000187:drug effects; D051379:Mice; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control*; D014364:Tryptophan; D000099152:Cadherin 5
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D015820:Cadherins; D000939:Epitopes; D014364:Tryptophan; D000099152:Cadherin 5